ClinicalTrials.gg
CompletedNCT04214652Updated Feb 1, 2024Results posted

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

A Phase 3 interventional study of IDP-126 Gel and IDP-126 Vehicle Gel in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..

Enrollment
22nd of 35
180 · median 247
Started
2020
with 1 other
Phase 3
13 of 36
none open now
Registered
32nd of 36
by date

Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 22nd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2020, is one of 13 in phase 3, and was the 32nd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Acne Vulgaris by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 9 years of age and older.
  • Written and verbal must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
  • Subject must have an Evaluator's Global Severity Score (EGSS) of 3 (moderate) or 4 (severe) at the baseline visit.
  • Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100.
  • Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150.
  • Subjects with 2 or fewer facial nodules.

Exclusion criteria

Exclusion Criteria:

  • Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, rosacea, gram negative folliculitis, dermatitis, eczema.
  • Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
  • Subjects with more than 2 facial nodules.
  • Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.
  • Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study.
  • Treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area.
  • Subjects who have not undergone specified (s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area.
  • Subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications.
  • Subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    IDP-126 Gel

    Drug: IDP-126 Gel

  • Placebo comparator
    IDP-126 Vehicle Gel

    Drug: IDP-126 Vehicle Gel

Interventions

  • IDP-126 Gel applied topically to the face once daily for 12 weeks.

  • DrugIDP-126 Vehicle Gel

    IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts

    Time frame: 12 weeks

  2. Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts

    Time frame: 12 weeks

  3. Percentage of Participants With Success on the Evaluator's Global Severity Score

    Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: 12 weeks

Secondary outcomes

  1. Inflammatory Lesion Count Percentage Changes at Week 4, 8, and 12

    Time frame: Baseline to Week 4, 8, 12

  2. Noninflammatory Lesion Count Percentage Changes at Week 4, 8, and 12

    Time frame: Baseline to Week 4, 8, 12

  3. Percentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 12

    The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: 12 weeks

07

Results

Posted Feb 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneIDP-126 GelIDP-126 Vehicle Gel
Started12060
Completed10756
Not completed134

Outcome measures

PrimaryAbsolute Change From Baseline to Week 12 in Inflammatory Lesion Counts
Time frame:
12 weeks
Reported as:
Least squares mean · lesion counts
Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts
lesion countsIDP-126 GelIDP-126 Vehicle Gel
Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts-30.1 ± 9.64-20.8 ± 9.90
PrimaryAbsolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
Time frame:
12 weeks
Reported as:
Least squares mean · lesion counts
Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
lesion countsIDP-126 GelIDP-126 Vehicle Gel
Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts-35.2 ± 14.48-22.0 ± 14.27
PrimaryPercentage of Participants With Success on the Evaluator's Global Severity Score

Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Success on the Evaluator's Global Severity Score
percentage of participantsIDP-126 GelIDP-126 Vehicle Gel
Percentage of Participants With Success on the Evaluator's Global Severity Score50.520.5
SecondaryInflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
Time frame:
Baseline to Week 4, 8, 12
Reported as:
Least squares mean · percentage change
Inflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
percentage changeIDP-126 GelIDP-126 Vehicle Gel
Week 4-57.40 ± 29.412-41.62 ± 26.854
Week 8-70.38 ± 27.018-47.62 ± 26.343
Week 12-80.13 ± 25.274-56.18 ± 25.149
SecondaryNoninflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
Time frame:
Baseline to Week 4, 8, 12
Reported as:
Least squares mean · percentage change
Noninflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
percentage changeIDP-126 GelIDP-126 Vehicle Gel
Week 4-45.07 ± 32.748-33.05 ± 29.290
Week 8-60.62 ± 28.041-45.54 ± 26.604
Week 12-73.26 ± 27.640-48.99 ± 27.345
SecondaryPercentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 12

The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 12
percentage of participantsIDP-126 GelIDP-126 Vehicle Gel
Percentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 1255.223.1

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDP-126 Gel0/120 (0%)0/120 (0%)18/120 (15%)
IDP-126 Vehicle Gel0/60 (0%)0/60 (0%)1/60 (1.7%)
Most frequent other events
Most frequent other events
EventIDP-126 GelIDP-126 Vehicle Gel
Application site painGeneral disorders18/1201/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDP-126 GelIDP-126 Vehicle GelTotal
Median17.0 (10 to 48)19.5 (11 to 43)18.0 (10 to 48)
Sex: Female, Male
Sex: Female, Male(Participants)IDP-126 GelIDP-126 Vehicle GelTotal
Female6937106
Male512374
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDP-126 GelIDP-126 Vehicle GelTotal
American Indian or Alaska Native000
Asian819
Native Hawaiian or Other Pacific Islander000
Black or African American12517
White9453147
More than one race000
Unknown or Not Reported617
Baseline Evaluator's Global Severity Score
Baseline Evaluator's Global Severity Score(Participants)IDP-126 GelIDP-126 Vehicle GelTotal
Moderate10957166
Severe11314
08

Study locations

13 sites
  • Bausch Site 205
    Rogers, Arkansas 72758, United States
  • Bausch Site 201
    Manhattan Beach, California 90266, United States
  • Bausch Site 207
    West Palm Beach, Florida 33406, United States
  • Bausch Site 208
    Boise, Idaho 83704, United States
  • Bausch Site 209
    Louisville, Kentucky 40241, United States
  • Bausch Site 202
    Brighton, Massachusetts 21350, United States
  • Bausch Site 212
    Detroit, Michigan 48202, United States
  • Bausch Site 206
    New York, New York 10022, United States
  • Bausch Site 203
    Gresham, Oregon 97030, United States
  • Bausch Site 204
    Johnston, Rhode Island 29190, United States
  • Bausch Site 213
    Winnipeg, MN R3M 3Z4, Canada
  • Bausch Site 210
    Oakville, Ontario L6J 7W5, Canada
  • Bausch Site 211
    Peterborough, Ontario K9J 5K2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Mar 2021, 13 months.

Results were first posted in Feb 2024, 2 years 10 months after primary completion. A results delay was requested in Mar 2022.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 13 months is close to that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2019
First posted
Jan 2, 2020
StartActual
Jan 27, 2020
Primary completionActual
Mar 18, 2021
CompletionActual
Mar 18, 2021
Results delay requested
Mar 15, 2022
Results first posted
Feb 1, 2024
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04214652
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Jan 27, 2020
Primary completion
Mar 18, 2021
Completion
Mar 18, 2021
Results posted
Feb 1, 2024
Last update
Feb 1, 2024

Study contacts

Anya Loncaric
study director · Bausch Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDP-126

Start the discussion